Cargando…
The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia
The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these r...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
American Psychiatric Association Publishing,
2020.
|
| Edición: | 3rd ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_on1223088072 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 201121s2020 dcu o ||| 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d DKU |d OCLCO |d LOA |d OCLCO |d OCLCF |d OCLCQ |d OCLCO |d OCLCQ |d OCLCL | ||
| 020 | |a 9780890424742 | ||
| 020 | |a 0890424748 | ||
| 035 | |a (OCoLC)1223088072 | ||
| 050 | 0 | 0 | |a RC514 |
| 060 | 1 | 0 | |a WM 203 |
| 082 | 0 | 0 | |a 616.89/8 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Association, American Psychiatric. | |
| 245 | 1 | 4 | |a The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia |h [electronic resource]. |
| 250 | |a 3rd ed. | ||
| 260 | |a Washington, D.C. : |b American Psychiatric Association Publishing, |c 2020. | ||
| 300 | |a 1 online resource (312 p.) | ||
| 500 | |a Description based upon print version of record. | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- Contents -- Acronyms/Abbreviations -- Introduction -- Rationale -- Scope of Document -- Overview of the Development Process -- Rating the Strengths of Guideline Statements and Supporting Research Evidence -- Proper Use of Guidelines -- Guideline Statement Summary -- Guideline Statements and Implementation -- Assessment and Determination of Treatment Plan -- Statement 1: Assessment of Possible Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement | |
| 505 | 8 | |a Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 2: Use of Quantitative Measures -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 3: Evidence-Based Treatment Planning -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations | |
| 505 | 8 | |a Quality Measurement Considerations -- Pharmacotherapy -- Statement 4: Antipsychotic Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 5: Continuing Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 6: Continuing the Same Medications | |
| 505 | 8 | |a Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 7: Clozapine in Treatment-Resistant Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 8: Clozapine in Suicide Risk -- Implementation | |
| 505 | 8 | |a Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 9: Clozapine in Aggressive Behavior -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 10: Long-Acting Injectable Antipsychotic Medications -- Implementation | |
| 500 | |a Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement. | ||
| 520 | |a The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these recommendations into clinical practice, with the goal of improving the quality of care and treatment outcomes for patients with schizophrenia. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Schizophrenia |x Treatment. | |
| 650 | 1 | 2 | |a Schizophrenia |x therapy |
| 650 | 6 | |a Schizophrénie |x Traitement. | |
| 650 | 7 | |a Schizophrenia |x Treatment |2 fast | |
| 758 | |i has work: |a AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA (Text) |1 https://id.oclc.org/worldcat/entity/E39PCXwMjX9WgHBvXp6phy8PkP |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Association, American Psychiatric |t The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia |d Washington, D.C. : American Psychiatric Association Publishing,c2020 |z 9780890424698 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=6373791 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6373791 | ||
| 994 | |a 92 |b IZTAP | ||